Merz M, Souto Filho JT, Voorhees PM, Einsele H, Schjesvold F, Scheffer Cliff ER, Mateos MV, Hungria V, Cohen YC, de Larrea CF, Beksac M, Landgren O, Usmani SZ, Costa LJ, Gagelmann N (2026)
T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis
J Hematol Oncol, 19 (1)
DOI 10.1186/s13045-026-01850-2, PubMed 42844619

Lonial S, Dimopoulos MA, Gavriatopoulou M, Kim K, Min CK, Oriol A, Moreira CCC, Quach H, Qiu L, Xia Z, Schjesvold F, Casas-Avilés I, Xu Y, Hungria V, Seval GC, Fang B, Kyriakou C, Prince HM, Zhuang J, Lin HC, Mateos MV, Špička I, Maiolino A, Vural F, Basu S, Dytfeld D, Fu C, Ho PJ, Joseph N, Low M et al. (2026)
Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial
Lancet Oncol (in press)
DOI 10.1016/S1470-2045(26)00450-X, PubMed 42790445

Gundesen MT, Vangsted AJ, Helleberg C, Haukås E, Silkjær T, Madsen JS, Asmussen JT, Teodorescu EM, Jensen BA, Slørdahl TS, Nielsen AA, Olsen DA, Søe K, Nahi H, Waage A, Abildgaard N, Schjesvold F, Lund T (2026)
Bone progression in multiple myeloma: Benefit of zoledronic acid for patients achieving at least Very Good Partial Response and prognostic value of bone turnover markers
Br J Haematol, 209 (3), 1076-1084
DOI 10.1111/bjh.70612, PubMed 42581608